Jefferies Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $79

Jefferies analyst Roger Song maintains $Structure Therapeutics(GPCR.US)$ with a buy rating, and maintains the target price at $79.According to TipRanks data, the analyst has a success rate of 30.2% an

Moomoo NewsJun 28 08:33 ET · Ratings

BMO Capital Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $100

BMO Capital analyst Evan Seigerman maintains $Structure Therapeutics(GPCR.US)$ with a buy rating, and maintains the target price at $100.According to TipRanks data, the analyst has a success rate of 4

Moomoo NewsJun 27 07:31 ET · Ratings

Pfizer's CEO announced the development of three new weight loss drugs, one of which is not a GLP-1 medication.

Pfizer's (PFE.US) CEO, Albert Bourla, said that the pharmaceutical company is testing three new weight loss drugs.

Zhitong FinanceJun 25 08:05 ET

Goldman Sachs and Cantor Fitzgerald have a tacit agreement that the monopoly of "Norris" in the weight loss drug market is difficult to change.

Two top Wall Street analysts have reached a consensus, emphasizing that global weight loss drug market leaders "Novo" may continue to dominate the highly profitable weight loss drug market.

Zhitong FinanceJun 23 21:39 ET

Lilly, Novo Nordisk to Dominate Weight Loss Therapy Market: SA Investing Summit

Seeking AlphaJun 23 14:00 ET

Obesity-Drug Developers Look at What's Next for a $100 Billion Market -- Barrons.com

Weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound, have launched a market that analysts expect will grow to $100 billion in 10 years. Drug developers from those firms and others are looking at ways to improve upon those big-selling drugs.

Barron'sJun 20 14:51 ET